Eisner Alvin, Falardeau Julie, Toomey Maureen D, Vetto John T
Neurological Sciences Institute, Oregon Health & Science University, Beaverton, Oregon 97006, USA.
Optom Vis Sci. 2008 May;85(5):301-8. doi: 10.1097/OPX.0b013e31816bea3b.
To determine whether women using anastrozole (an aromatase inhibitor, which suppresses estrogen synthesis) are likely to have retinal hemorrhages.
Fundus photographs were obtained for a study comparing effects on vision and the eye of anastrozole (1 mg/d) and tamoxifen (20 mg/d) for women receiving adjuvant endocrine therapy for early-stage breast cancer. Photographs (2 eyes per subject) were evaluated for hemorrhages by an ophthalmologist masked from identifying subject information. The presence of hemorrhages was assessed for 35 anastrozole users, 38 amenorrheic tamoxifen users, and 53 amenorrheic (peri- or postmenopausal) control subjects not using any endocrine medication. The age range was 43 to 69 years; only subjects reporting normal vision and healthy eyes were recruited. Photographs from 36 tamoxifen users from a previous study also were assessed. Views of the fundus extended appreciably beyond the posterior pole for all tamoxifen and anastrozole users, and for 38 of the control subjects. Photographic assessments were compared with medical history and blood pressure data, and optical coherence tomography was used for quantifying aspects of foveal shape that might be affected by vitreoretinal traction.
Four anastrozole users and no contemporaneous tamoxifen users but one previously tested tamoxifen user had retinal hemorrhages, in each case within the posterior pole. Two anastrozole users had a flame hemorrhage (in the retinal nerve fiber layer), and two had a blot hemorrhage (deeper in the retina). No control subjects were observed to have hemorrhages.
Anastrozole use appears to be associated with an increased prevalence of retinal hemorrhages. The hemorrhages may mark systemic vascular compromise resulting from estrogen depletion, and/or they may be consequences of vitreoretinal traction resulting from estrogen depletion. They may also depend on the use of medications for controlling common anastrozole-induced side effects. Prospective studies need to be conducted with larger numbers of subjects.
确定使用阿那曲唑(一种抑制雌激素合成的芳香化酶抑制剂)的女性是否可能发生视网膜出血。
对一项研究的受试者进行眼底照相,该研究比较了阿那曲唑(1毫克/天)和他莫昔芬(20毫克/天)对接受早期乳腺癌辅助内分泌治疗的女性视力和眼睛的影响。由一位不知道受试者信息的眼科医生对照片(每位受试者双眼)进行出血情况评估。对35名使用阿那曲唑的患者、38名闭经的他莫昔芬使用者以及53名未使用任何内分泌药物的闭经(围绝经期或绝经后)对照受试者进行出血情况评估。年龄范围为43至69岁;仅招募报告视力正常且眼睛健康的受试者。还评估了来自先前一项研究的36名他莫昔芬使用者的照片。所有使用他莫昔芬和阿那曲唑的患者以及38名对照受试者的眼底照片视野明显超出后极部。将照相评估结果与病史和血压数据进行比较,并使用光学相干断层扫描来量化可能受玻璃体视网膜牵引影响的黄斑形状方面。
4名使用阿那曲唑的患者发生视网膜出血,同期使用他莫昔芬的患者未发生,但有1名先前接受测试的他莫昔芬使用者发生视网膜出血,所有病例均发生在后极部。2名使用阿那曲唑的患者出现火焰状出血(位于视网膜神经纤维层),2名出现点状出血(在视网膜更深层)。未观察到对照受试者有出血情况。
使用阿那曲唑似乎与视网膜出血患病率增加有关。这些出血可能标志着雌激素缺乏导致的全身血管受损,和/或可能是雌激素缺乏导致的玻璃体视网膜牵引的结果。它们也可能取决于用于控制阿那曲唑常见副作用的药物使用情况。需要对更多受试者进行前瞻性研究。